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Abstract
Burkholderia pseudomallei is a Gram-negative bacillus that is the causative agent of melioidosis. The bacterium is inherently
resistant to many antibiotics and mortality rates remain high in endemic areas. The lipopolysaccharide (LPS) and capsular
polysaccharide (CPS) are two surface-associated antigens that contribute to pathogenesis. We previously developed two
monoclonal antibodies (mAbs) specific to the CPS and LPS; the CPS mAb was shown to identify antigen in serum and urine
from melioidosis patients. The goal of this study was to determine if passive immunization with CPS and LPS mAbs alone
and in combination would protect mice from a lethal challenge with B. pseudomallei. Intranasal (i.n.) challenge experiments
were performed with B. pseudomallei strains 1026b and K96423. Both mAbs provided significant protection when
administered alone. A combination of mAbs was protective when low doses were administered. In addition, combination
therapy provided a significant reduction in spleen colony forming units (cfu) compared to results when either the CPS or
LPS mAbs were administered alone.
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Introduction
Melioidosis occurs primarily in the tropics and is caused by the
soil dwelling pathogen B. pseudomallei. Infection with B. pseudomallei
creates many clinical challenges, the most obvious being resistance
to commonly prescribed antibiotics [1,2,3]. In addition, recom-
mended treatment with effective antibiotics is intensive, consisting
of a short parenteral phase followed by a long oral phase [4].
Relapse rates can approach 25%, with nearly half of these patients
developing septicemia [5]. A recent prospective study determined
that the incidence of melioidosis has increased in northeast
Thailand from 1997–2006 and the mortality rate during this
period was nearly 43% [6]. In the same geographical region,
melioidosis is the third most common cause of death from
infectious disease after acquired immunodeficiency syndrome
(AIDS) and tuberculosis [6]. In regions of northern Australia,
where intensive care treatment is more readily available, the
mortality rate is still alarmingly high at 20% [2,7].
B. pseudomallei encodes many well-established virulence factors,
two of which are the capsular polysaccharide (CPS) and
lipopolysaccharide (LPS) [8,9,10,11,12,13,14]. CPS is an un-
branched homopolymer of 1,3-linked 2-O-acetyl-6-deoxy-b-D-
manno-heptopyranose residues. [15]. A subtractive hybridization
study determined that the CPS is a major virulence factor
necessary for pathogenicity in a Syrian hamster model of acute
melioidosis [8]. In the same study, a CPS mutant strain was
10,000-fold less virulent when compared to a wild type strain. CPS
also reduces the amount of complement factor C3b deposited on
the bacterial surface, which in turn confers resistance to
phagocytosis [9].
B. pseudomallei LPS contributes to pathogenesis in vitro and in vivo.
The O-antigen component of LPS is an unbranched polymer of
1,3 linked b-D-glucopyranose-(1–3)-6-deoxy-a-L-talopyranose res-
idues [15,16]. A B. pseudomallei O-antigen mutant is more
vulnerable to killing by a mouse macrophage cell line [11] and
more susceptible to killing through the alternative complement
pathway [12,13]. In human melioidosis cases, survivors develop an
IgG3 antibody response specific to LPS [10,14].
The goal of this study was to evaluate the therapeutic potential
of two mAbs specific to the LPS and the manno-heptose CPS of B.
pseudomallei [17]. Our study (i) challenged mice with two strains of
B. pseudomallei via the i.n. route, (ii) administered mAbs alone and
in combination, and (iii) assessed survival, spleen colony forming
units (cfu), and organ abscess formation. The data generated
supports and strengthens previous findings that indicate targeting
B. pseudomallei surface expressed polysaccharides for treatment of
melioidosis may be a sensible endeavor.
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Immunization of mice and production of mAbs
Production of IgG3 mAbs 4C7 (LPS) and 3C5 (CPS) has been
previously described [17]. Briefly, B. pseudomallei strain 1026b was
grown overnight at 37uC in brain heart infusion media under
BSL-3 containment practices. BALB/c mice were then immunized
with 2610
8 heat-inactivated B. pseudomallei (80uC for 2.5 h) by the
intraperitoneal (i.p.) route every two weeks for an eight-week
period [18]. An enzyme-linked immunosorbent assay, with heat-
inactivated strain 1026b in the solid phase, was used to assess
antibody titers to B. pseudomallei [18]. The last immunization was
administered three days prior to harvest of spleens. Hybridoma
cells were produced as previously described [19]. Western blot
analysis was done to identify hybridoma cell lines that were
producing mAbs reactive with purified CPS or producing a ladder
pattern characteristic of LPS binding. Hybridoma cell lines were
grown in Integra CL 1000 culture flasks (Integra Biosciences) and
mAbs were purified by affinity chromatography over a protein-A
column.
Immunohistochemistry (IHC)
mAbs 3C5 and 4C7 were coupled to horseradish peroxidase
(HRP) using the EZ-Link Plus
TM Activated Peroxidase Kit (Pierce)
followed by purification with a Pierce Conjugate Purification Kit.
Tissue sections were deparaffinized using Histoclear (National
Diagnostics) followed by a graded ethanol series. Hydrogen
peroxide (0.3%) was applied to tissues to reduce endogenous
peroxidase activity. Sections were incubated in 0.15 M glycine in
PBS for 15 min, rinsed in PBS, and then incubated in a blocking
solution (1% BSA/PBS) for 30 min. HRP-labeled mAbs were
diluted to 15 mg/ml in blocking solution and applied to the tissues
for 3 h at room temp. Slides were rinsed with PBS followed by
treatment with diaminobenzidine (DAB) substrate solution (Im-
mPACT
TM DAB Peroxidase Substrate, Vector Laboratories).
Slides were washed in water and counterstained using hematox-
ylin. Microscopy was performed using a Nikon Eclipse E800
microscope and a Spot RT color digital camera (Diagnostic
Instruments).
Intranasal challenge model
Two murine melioidosis infection models were used under
ABSL-3 containment practices. The first model began by injecting
female BALB/c mice with one dose of various concentrations of
mAb(s) (3C5, 4C7, or IgG3 subclass control mAb) by the i.p. route,
18 h prior to challenge. A vial of frozen B. pseudomallei 1026b was
thawed and diluted in PBS to a concentration of approximately
5000 cfu/25 ml (15 LD50). Mice were anesthetized, held vertically,
and 25 ml of the inoculum was released into the nares for
inhalation. Following challenge, the inoculum was back titrated on
agar plates to confirm delivered dose. Mice were weighed prior to
inoculation, daily for 10 days, then twice weekly until 3 or 6 weeks
post-challenge. Using this model, control mice became debilitated
and required euthanasia 3–4 days post-challenge. At necropsy, the
internal organs were excised aseptically and examined by one of
two veterinarians for the presence of abscesses (the number and
size of each abscess were noted). Spleens were then homogenized
in 1 ml of LB broth using a mixer mill. The homogenate (100 ml)
was plated on LB plates and colonies counted 2 days later to
determine bacterial loads.
The second i.n. challenge model was modified from a previously
described protocol [20]. Briefly, female BALB/c mice were
administered various doses of mAb via the i.p. route 18 h prior
to infection with B. pseudomallei strain K96423. Mice were then
challenged via the i.n. route (50 ml) with approximately 600 cfu (2
LD50). Mice were weighed prior to inoculation and monitored for
21 days post-infection. Using this model, control mice became
debilitated and required euthanasia 4–6 days post-challenge. For
all passive immunization experiments, control mice were untreat-
ed or were administered an isotype control IgG3 mAb (F26G3)
specific to the capsule of Bacillus anthracis [19,21].
Statistics
All statistical analysis was performed with Prism 5 software
(GraphPad Software, Inc.) Survival curves were generated by use
of Kaplan-Meier estimators. The survival distributions of each
treatment group vs. control mice were compared via the log-rank
(Mantel-Cox) test. Significance of spleen cfu vs. control mice were
calculated with Fisher’s exact test.
Ethics Statement
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocols were approved
by the Animal Care and Use Committees of Colorado State
University (Protocol #09-001A) and the University of Texas
Medical Branch (Protocol #0503014A). Mice were anesthetized
by intraperitoneal injection of a ketamine/xylazine solution.
Results
Our previous study determined that IgG3 mAbs 4C7 and 3C5
are reactive with B. pseudomallei LPS and CPS, respectively [17]. By
Western blot mAb 4C7 produces a ladder pattern typical of B.
pseudomallei LPS binding [22,23,24,25] and mAb 3C5 is reactive
with purified CPS that was structurally verified by nuclear
magnetic resonance (NMR) [17]. Before proceeding with passive
immunization studies we confirmed by immunofluorescence that
mAbs 3C5 and 4C7 are reactive with the exterior of B. pseudomallei
cells (data not shown).
The mAbs were tested for the ability to provide passive
protection in a murine model of pulmonary melioidosis. An initial
study determined that i.n. challenge with 5000 cfu (equivalent to
15 LD50)o fB. pseudomallei strain 1026b caused development of
acute disease in BALB/c mice (data not shown). At this challenge
dose, mice were euthanized within 2–3 days. The initial passive
immunization study consisted of i.p. administration of 1 mg of
mAb 3C5 or 4C7 alone and 1 mg of each mAb in combination;
these doses did not cause any adverse effects in the mice. Mice
were challenged 18 h post mAb treatment with an estimated dose
of 5000 cfu of B. pseudomallei and monitored for 21 days. At this
dose all infected mice showed reduced activity and had ruffled fur.
Administration of mAb 3C5 protected 86% (6/7) of the infected
mice and mAb 4C7 protected 50% (4/8) (Fig. 1; Table 1, Exp. 1).
In addition, all of the mice that received both mAbs in
combination (1 mg of each mAb/mouse) survived the challenge.
All of the mice from this initial study lost weight 1–2 days following
challenge, however, mice that survived began to gain weight back
by day 6 and appeared healthy by day 21. Control mice were
injected with 1 mg of an IgG3 mAb specific for the capsule of B.
anthracis [19,21]; these mice became moribund and were
euthanized at day 3.
In addition to survival, the effect the mAbs had on development
of spleen cfu and abscess formation was determined. Spleen
cultures were determined for survivors only. Spleen culture data is
included for each treatment group in Table 1. Additionally, mice
that did not survive the challenge dose were assumed to develop
spleen cfu in order to allow for a statistical evaluation of spleen cfu
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71% (5/7) and 88% (7/8) of mice treated with mAbs 3C5 and
4C7, respectively (Table 1; Exp. 1). A statistically significant
reduction in spleen cfu occurred when both mAbs were
administered in combination; all six of the mice in this group
did not develop spleen cfu. Abscess formation developed in 75%
(3/4) of the surviving mice that were administered mAb 4C7,
whereas mice administered mAb 3C5 or both mAbs in
combination did not develop abscesses.
A dose-response experiment was performed to estimate the
median effective dose (ED50) of each mAb (Fig. 2A; Table 1, Exp.
2). Experiment 1 suggested that mAb 4C7 was not as protective as
mAb 3C5. Therefore, a higher starting dose of mAb 4C7 was used
in the dose response experiment compared to mAb 3C5. In
addition mice were monitored for 42 days to determine if survival
rates and gross pathology would be adversely affected. Three of
the four doses of mAb 3C5 provided highly significant protection
with the 125 mg dose providing optimal protection (88% survival).
The 250 mg dose of mAb 3C5 did not protect any of the mice.
This result was most likely due to experimental error since the
doses higher and lower than 250 mg were protective, and this lack
of protection was not observed in a second experiment with the
K96243 strain (Fig. 3). At the highest dose of mAb 4C7 (2000 mg)
no protection was achieved, however, at 1000 mg half of the mice
survived (4/8) (similar to Exp. 1). Lower doses of mAb 4C7 did not
protect as many mice as mAb 3C5. None of the doses of either
mAb produced a statistically significant reduction in spleen cfu,
similar to the individual doses in Exp. 1.
Complete protection with no indication of pathology was
achieved when 1 mg of each mAb was administered in
combination. Therefore, an additional combination experiment
with multiple doses was performed (Fig. 2B; Table 1, Exp. 3) in
order to access synergy [26,27]. In designing the synergy
experiment the highest doses were estimated ED50 values of each
mAb based on the results from Fig. 2A. Therefore, the highest
dose administered was 500 mg of mAb 3C5 combined with
1000 mg of mAb 4C7. Three smaller doses (twofold serial dilution
from the highest doses) were also administered and mice were
monitored for 42 days. All doses provided significant protection;
the lowest three doses each protected 7/8 mice. In addition, the
three lowest doses of combination therapy significantly reduced
spleen cfu, a reduction not seen in any of the individual mAb dose
experiments.
An additional dose-response experiment was performed to
analyze protection against a different strain of B. pseudomallei
(K96243). mAb 3C5 protected 7/8 mice at the 125 mg dose
(Table 1; Exp. 2), so a four-fold dilution of mAb doses were used
(from 1000 mgt o1 6mg) in this experiment to determine potency
at lower doses. Mice were infected via the i.n. route with 2 LD50 of
B. pseudomallei strain K96243 and monitored for 21 days. All of the
doses provided statistically significant protection compared to
control mice. In accordance with the previous experiments, CPS
mAb 3C5 appeared to be more potent than LPS mAb 4C7 at
identical doses; however, this difference was not statistically
significant.
Abscess formation occurred in 20% (13/64) of surviving mice
(Exp. 1–3) with the most common site being spleen (67%) followed
by liver (20%) and lung (13%) (data not shown). The ability of CPS
mAb 3C5 and LPS mAb 4C7 to detect antigen within an abscess
by IHA was determined. Spleen tissue sections were used since the
percentage of abscess formation in this organ was highest. Spleens
were harvested from control mice that did not receive mAb
treatment. Fig. 4 displays an IHC image of the outer edge of an
abscess where CPS was identified with HRP-labeled mAb 3C5
(brown) surrounded by splenic tissue (blue). mAb 4C7 was unable
to detect LPS within a section of the same splenic abscess. It is
unclear whether this is due to (i) alteration of the LPS structure
during preparation of the tissue for IHC (ii) the CPS antigen being
more abundant on the bacterial cell surface or (iii) the CPS being
more accessible to antibody when contained within an abscess.
Discussion
A number of successful passive immunization studies have been
performed that administered either polyclonal (pAb) [28,29,30] or
monoclonal antibodies [18,29,31,32] reactive with polysaccharides
in an effort to understand the pathogenesis of B. pseudomallei. These
studies administered antibodies reactive with LPS and/or
uncharacterized high molecular weight capsular polysaccharides.
There are four known capsular structures in B. pseudomallei [33],
which complicates the identification of which specific capsular
polysaccharide was targeted in the previous studies. Therefore,
one goal of the current research was to characterize the protection
afforded by CPS mAb 3C5, which has been previously shown to
bind to purified (NMR verified) 2-O-acetyl-6-deoxy-b-D-manno-
heptopyranose capsule [17].
The current report provides additional support for the
development of vaccines and therapeutic antibodies targeting
surface exposed polysaccharides of B. pseudomallei. The data
demonstrate that LPS mAb 4C7 is able to provide significant
passive protection against two different strains of B. pseudomallei.
This is consistent with previous passive immunization studies that
targeted B. pseudomallei LPS [18,28,29,30,31]. Interestingly, the
2000 mg dose of mAb 4C7 did not protect any of the mice, while
the 1000 mg dose protected half of the mice (Table 1, Exp. 1 & 2).
This may be due to a prozone phenomenon, in that high doses of
polysaccharide-specific mAbs have been shown to inhibit protec-
tive effects [34,35,36]. mAb 3C5, which is specific to the manno-
heptose capsule of B. pseudomallei, also provided significant passive
protection. In addition, mAb 3C5 was able to protect more mice at
lower doses compared to mAb 4C7, although this was not
Figure 1. Protection in passively immunized mice following i.n.
challenge with B. pseudomallei strain 1026b. BALB/c mice were
administered 1 mg of either CPS IgG3 mAb 3C5 or LPS IgG3 mAb 4C7
alone or 1 mg of each mAb in combination by the i.p. route. Intranasal
challenge was performed 18 h later with 15 LD50 of B. pseudomallei.
Mice were monitored for 21 days after which gross pathology and
spleen cfu were determined on survivors (Table 1). Control mice were
treated with 1 mg of an irrelevant IgG3 mAb. p values of survival vs.
controls are listed in Table 1.
doi:10.1371/journal.pone.0035386.g001
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targeted unknown capsular polysaccharides with passive mAb
therapy [18,31,32]. Our study appears to be the first to provide
passive protection with a mAb reactive to a specific capsular
polysaccharide.
The mAbs in this study were individually protective; therefore
we anticipated that the mAbs would be more effective if
administered in combination. An informative study by Jones et
al. determined that administration of a combination of LPS,
unknown protein, and high molecular weight polysaccharide
specific antibodies was able to protect against an i.p. challenge
with B. pseudomallei [18]. When CPS mAb 3C5 and LPS mAb 4C7
were administered in combination the three lowest dose
combinations were able to protect 88% of the mice (21/24). This
high level of protection suggested synergistic effects between the
two mAbs. A statistical assessment of synergy [26,27] was
performed with CalcuSyn software, however, values could not
be calculated due to the high levels of protection at the lowest
combination doses. The result adds to the previous study by Jones
et al. by achieving protection from i.n. challenge with combination
therapy consisting of mAbs specific to LPS and the manno-heptose
capsule.
At all doses, bacterial colonization of the spleen was not
effectively controlled when mAbs were administered alone.
Combination therapy at the lower doses resulted in a significant
reduction in the development of spleen cfu and low numbers of
abscesses in survivors. The two intermediate combination doses
summarized in Table 1 (Exp. 3) illustrate this point well. Of the 14

















CPS (3C5) LPS (4C7) IgG3 control
Experiment 1 - B. pseudomallei strain 1026b
- - 1000 21 0/8 -- -
1000 - - 21 6/7 (,0.01) 5/7 (=0.20) 0,0,1,2,106,T 0/6
- 1000 - 21 4/8 (,0.01) 7/8 (=0.50) 0,12,T,T 3/4
1000 1000 - 21 6/6 (,0.01) 0/6 (,0.01) 0,0,0,0,0,0 0/6
Experiment 2 - B. pseudomallei strain 1026b
- - - 42 0/8 - - -
1000 - - 42 6/8 (,0.01) 5/8 (=0.10) 0,0,0,214,T,T 1/6
500 - - 42 4/8 (,0.01) 5/8 (=0.10) 0,0,0T 1/4
250 - - 42 0/8 (=0.48) 8/8 (.0.50) - -
125 - - 42 7/8 (,0.01) 5/8 (=0.10) 0,0,0,4,5,T,T 3/7
- 2000 - 42 0/8 (,0.20) 8/8 (.0.50) - -
- 1000 - 42 4/8 (=0.01) 7/8 (=0.50) 0,T,T,T 0/4
- 500 - 42 1/8 (=0.06) 7/8 (=0.50) 0 0/1
- 250 - 42 0/8 (=0.01) 8/8 (.0.50) - -
Experiment 3 – B. pseudomallei strain 1026b
- - - 42 0/8 - - -
500 1000 - 42 5/8 (,0.01) 7/8 (=0.50) 0,2,6,T,T 2/5
250 500 - 42 7/8 (,0.01) 2/8 (,0.01) 0,0,0,0,0,0,1 0/7
125 250 - 42 7/8 (,0.01) 2/8 (,0.01) 0,0,0,0,0,0,T 1/7
62.5 125 - 42 7/8 (,0.01) 4/8 (=0.04) 0,0,0,0,128,T,T 2/7
Experiment 4 – B. pseudomallei strain K96423
- - 1000 21 0/8 - - -
1000 - - 21 6/8 (,0.01) -- -
250 - - 21 3/8 (,0.01) -- -
62.5 - - 21 4/8 (,0.01) -- -
16 - - 21 2/8 (,0.01) -- -
- 1000 - 21 2/8 (,0.01) -- -
- 250 - 21 3/8 (,0.01) -- -
- 62.5 - 21 1/8 (,0.01) -- -
-1 6 - 2 1 2/8 (=0.02) -- -
ap value vs. controls determined from Kaplan-Meier survival plots by log-rank (Mantel-Cox) test, bold values are statistically significant (p,0.05).
bpositive spleen cfu was determined on survivors and assumed to occur in mice that died before study endpoint.
cp values vs. controls determined by Fisher’s exact test, bold values are statistically significant (p,0.05).
dspleen cfu was assessed on survivors only; values indicate cfu determined by plating 100 ml from a 1 ml spleen homogenate; T indicates too numerous to count.
edetermination of abscess formation on internal organs was performed on survivors only.
doi:10.1371/journal.pone.0035386.t001
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developed an abscess. As mentioned, one previous study found
combination therapy to be effective against a B. pseudomallei i.p.
challenge [18]. However, most of the surviving mice developed
abscesses on the spleen and liver [18]. Our data suggest a benefit
of low dose combination therapy based on the significant
reduction in spleen cfu and low levels of abscesses on internal
organs of survivors. It is not clear whether one of the mAbs is more
effective at controlling spleen cfu and abscess formation, however
it is interesting that only mAb 3C5 (and not mAb 4C7) was able to
identify CPS present in abscesses by IHC (Fig. 4).
There is no effective vaccine available to prevent melioidosis
and treatment of the disease remains challenging. Although many
vaccination studies in animals have been completed, none have
elicited sterilizing immunity [37]. Antibiotic treatment in humans
is also difficult; even with the administration of appropriate
antibiotics, relapse rates remain high [5,38]. Therefore, adjuncts
to antibiotic therapy are greatly needed. Several studies have been
undertaken to identify effective adjunctive treatments. One study
administered low-dose hydrocortisone, along with ceftazidime, for
the treatment of severe sepsis in mice, although this did not
provide a survival benefit [39]. Cheng et al. concluded that
adjunct treatment with granulocyte colony-stimulating factor (G-
CSF) might have contributed to reduction in mortality among
melioidosis patients with septic shock [40]. However, the benefit of
G-CSF treatment was not supported in a murine model of
melioidosis or an in vitro whole blood bactericidal assay [41,42].
Finally, an encouraging study by Propst et al. concluded that
administration of gamma interferon improves survival in a murine
model of pulmonary melioidosis [43].
The current study has determined that B. pseudomallei polysac-
charide specific mAbs can provide significant protection in a
murine model of pulmonary melioidosis when administered alone.
Significant protection was also achieved when both mAbs were
administered in combination. In addition, development of spleen
cfu was significantly reduced when mAbs were administered in
combination as compared to mAbs administered alone. Admin-
Figure 2. Effect of mAb dose and combination therapy in mice challenged with B. pseudomallei strain 1026b. Mice were administered
mAb(s) by the i.p. route followed 18 h later by i.n. challenge with 15 LD50 of B. pseudomallei. (A) Dose-response experiment in which mice were
treated with the doses (mg) listed of each mAb alone. (B) Multiple doses of mAbs 3C5 and 4C7 were administered in combination at the doses (mg)
listed. Mice were monitored for 42 days after which gross pathology and spleen cfu were determined on survivors (Table 1). Control mice were not
treated with mAb. p values of survival vs. controls are listed in Table 1.
doi:10.1371/journal.pone.0035386.g002
Figure 3. Protection in passively immunized mice following i.n.
challenge with B. pseudomallei strain K96243. mAbs were
administered by the i.p. route at the doses (mg) listed. Intranasal
challenge was performed 18 h later with 2 LD50 of B. pseudomallei. Mice
were monitored for 21 days. Control mice were treated with 1 mg of an
irrelevant IgG3 mAb. p values of survival vs. controls are listed in Table 1.
doi:10.1371/journal.pone.0035386.g003
Figure 4. Detection of CPS within a splenic abscess by IHC.
Organs were harvested from control BALB/c mice (Fig. 3) that were
infected with B. pseudomallei strain 1026b. A tissue section from a
spleen that contained multiple large abscesses is shown (left panel).
Location of CPS was identified by HRP-labeled mAb 3C5 (brown). Box
within the panel on the left indicates the boundary of an abscess and
surrounding normal splenic tissue (tissue within box is magnified in
right panel). White scale bars indicate 50 mm.
doi:10.1371/journal.pone.0035386.g004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35386istration of both protective antibodies appeared to elicit synergistic,
or at the very least additive, effects in our studies. The
combination therapy was an attempt to mimic the natural
polyclonal response to infection. Therefore, the mAbs described
in this report may have potential as an adjunct therapy to
antibiotics. Future studies will evaluate the benefit of administra-
tion of relevant antibiotics along with CPS and LPS mAbs (alone
and in combination). If mAb adjunct therapy is effective,
additional studies will evaluate the treatment in a post-challenge
model. Such a treatment may aid in reducing the development of
latent foci that would eventually cause relapse of disease.
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